Rates for Breast Cancer Characteristics by Estrogen and Progesterone Receptor Status in the Major Racial/Ethnic Groups (original) (raw)
References
Early Breast Cancer Trialists' Collaborative Group: Poly-chemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 352: 930–942, 1998 Google Scholar
Elledge RM, Fuqua SAW: Estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia, 2000, pp 471–488
Harris JR, Lippman ME, Morrow M, Osborne CK (eds): Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia, 2000 Google Scholar
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 351: 1451–1467, 1998 Google Scholar
Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28: 9–20, 1993 Google Scholar
Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Cont 10: 431–437, 1999 Google Scholar
Tarone RE, Chu KC: The greater impact of menopause on ER than ER+cancer incidence: a possible explanation. Cancer Causes Control 13: 7–14, 2002 Google Scholar
Chu KC, Anderson WF, Fritz A, Ries LG, Brawley: Frequency of breast cancer characteristics by their joint estrogen and progesterone receptor status for multiple racial/ethnic groups. Cancer 92: 37–45, 2000 Google Scholar
Surveillance, Epidemiology and End Results SEER Program: SEER Cancer Incidence Public Use-Database, 1973–1998. SEER *Stat:(4._0) 2001
Shambaugh EM, Ries LAG, Kruse MA, Platz CE, Ryan RF, Weiss MA: SEER Extent of Disease - 1988 Codes and Coding Instructions. 2nd edn, 1992
Seiffert JE: SEER Program: Comparative Staging Guide for Cancer. Version 1._1, 1993
Percy CL, Holton VV, Muir C: International Classification of Diseases for Oncology. 2nd edn, World Health Organization, Geneva, 1990 Google Scholar
Simpson JF, Page DL: Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 102(suppl): S3–S8, 1994 Google Scholar
Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57: 4987–4991, 1997 Google Scholar
Anderson E, Clarke RB, Howell A: Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 3: 23–35, 1998 Google Scholar
Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP: Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 188: 237–244, 1999 Google Scholar
Russo J, Russo IH: Cellular basis of breast cancer susceptibility. Oncol Res 11: 169–178, 1999 Google Scholar
Fuqua SAW, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC: A hypersensitive estrogen receptor-á mutation in premalignant breast lesions. Cancer Res 60: 4026–4029, 2000 Google Scholar
Potter JD, Cerhan JR, Sellars TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomark Prev 4: 319–326, 1995 Google Scholar
Yoo KY, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H, Dubrow R: Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol 146: 307–314, 1997 Google Scholar
Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151: 703–714, 2000 Google Scholar
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenshcikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale A, Brown P, Botstein D: Molecular portraits of human breast tumors. Nature 406: 747–752, 2000 Google Scholar
Chu KC, Tarone RE, Brawley: Breast cancer trends for black women compared with white women. Arch Fam Med 8: 521–528, 1999 Google Scholar
Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB: Ethnicity and variation in breast cancer incidence. Int J Cancer 73: 349–355, 1997 Google Scholar
Katzenellenbogen BS, Katzenellenbogen JA: Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor molecules and importance in breast cancer. Breast Cancer Res 2: 335–344, 2000 Google Scholar
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 286: 2251–2256, 2001 Google Scholar
Robertson JFR: Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73: 5–12, 1996 Google Scholar
Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer 53: 630–643, 1984 Google Scholar